uniQure N.V. (LON:0EE0)
12.75
-0.26 (-2.03%)
At close: Feb 21, 2025
uniQure Revenue
uniQure had revenue of $2.29M USD in the quarter ending September 30, 2024, with 62.54% growth. This brings the company's revenue in the last twelve months to $28.59M, down -74.45% year-over-year. In the year 2023, uniQure had annual revenue of $15.84M, down -85.12%.
Revenue (ttm)
$28.59M
Revenue Growth
-74.45%
P/S Ratio
n/a
Revenue / Employee
$59.56K
Employees
480
Market Cap
542.77M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.84M | -90.64M | -85.12% |
Dec 31, 2022 | 106.48M | -417.52M | -79.68% |
Dec 31, 2021 | 524.00M | 486.49M | 1,296.82% |
Dec 31, 2020 | 37.51M | 30.23M | 415.23% |
Dec 31, 2019 | 7.28M | -4.00M | -35.48% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 43.19B |
GSK plc | 31.38B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Genus | 668.80M |
uniQure News
- 16 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 16 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 16 days ago - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - PRNewsWire
- 20 days ago - uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 24 days ago - uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS - GlobeNewsWire
- 6 weeks ago - uniQure prices equity offering - Seeking Alpha
- 6 weeks ago - uniQure Announces Pricing of its Public Offering - GlobeNewsWire
- 6 weeks ago - uniQure filed for automatic mixed securities shelf - Seeking Alpha